TITLE

Inhibiteurs de tyrosine-kinase de 2 génération et associations: perspectives

AUTHOR(S)
Coiteux, V.
PUB. DATE
October 2012
SOURCE
Oncologie;Oct2012, Vol. 14 Issue 10/11, p601
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Second-generation tyrosine-kinase inhibitors enable an earlier and higher quality molecular response to be achieved than with imatinib in patients suffering from CML in chronic phase at diagnosis. This implies that in the future a larger number of patients will be candidates for the discontinuation of treatment. However, the majority of patients maintain a detectable residual disease despite their CMR4.5 status.Moreover, in the STIMstudy, more than half the patients who stopped Imatinib after 2 years of CMR, had a molecular relapse. Indeed, it has been shown that quiescent Philadelphia-positive cells recover upon ceasing tyrosine-kinase inhibitors (TKIs). The association of other molecules with TKI, acting by routes other than AbI inhibition, appears to be an interesting and logical option in the goal of eradicating the disease. Several research avenues exist. SMO, CXCR4, STAT5 inhibitors and PEG-IFN act by specific mechanisms which will be detailed here. The PEG-IFN and imatinib combination has shown very promising results, and TKI2 and PEGIFN tests are in progress. No data testing combinations of TKI2 and other molecules on a series of patients has been published to date. We will discuss here the rationale, the issues of this type of therapy and the perspectives in the treatment of CML.
ACCESSION #
83780067

 

Related Articles

  • Imatinib en première ligne dans la LMC en 2012: un traitement « dépassé » ? Giraudier, S. // Oncologie;Oct2012, Vol. 14 Issue 10/11, p579 

    The initial management of chronic myeloid leukemia (CML) in chronic phase is now based solely on treatment with tyrosine-kinase inhibitor (TKI). The development of second generation inhibitors and their use in first-line treatment raises the issue of choice of TKI in the first prescription....

  • Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines? RUMJANEK, Vivian M.; VIDAL, Raphael S.; MAIA, Raquel C. // Bioscience Reports;2013, Vol. 33 Issue 6, p875 

    The hallmark of CML (chronic myeloid leukaemia) is the BCR (breakpoint cluster region)-ABL fusion gene. CML evolves through three phases, based on both clinical and pathological features: a chronic phase, an accelerated phase and blast crisis. TKI (tyrosine kinase inhibitors) are the treatment...

  • Improving upon the promise of targeted therapy of human malignancy: chronic myeloid leukemia as a paradigm. Shah, Neil P. // Cancer Chemotherapy & Pharmacology. Supplement;Dec2006, Vol. 58, p49 

    The small molecule BCR-ABL-selective kinase inhibitor imatinib is the single most effective medical therapy for the treatment of chronic myeloid leukemia (CML). Although imatinib is highly effective initially and generally well tolerated, for patients who undergo relapse or disease progression...

  • Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy. Pytel, Dariusz; Sliwinski, Tomasz; Poplawski, Tomasz; Ferriola, Deborah; Majsterek, Ireneusz // Anti-Cancer Agents in Medicinal Chemistry;2009, Vol. 9 Issue 1, p66 

    Tyrosine kinases (TKs) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth. Constitutive activated TKs stimulate multiple signaling pathways responsible for DNA repair, apoptosis, and cell proliferation. During the...

  • Targeted therapies for CML: practical considerations and comparisons. Blamble, Debbie; Michaud, Laura Boenhnke // Hem/Onc Today;8/10/2008, Vol. 9 Issue 14, p14 

    The article discusses other targeted therapies that have been approved for Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML), since the approval of imatinib. Among them are two new tyrosine kinase (TK) inhibitors, dasatinib and nilotinib. A comparison between dasatinib, imatinib...

  • Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Tolomeo, Manlio; Dieli, Francesco; Gebbia, Nicola; Simoni, Daniele // Anti-Cancer Agents in Medicinal Chemistry;2009, Vol. 9 Issue 8, p853 

    Imatinib mesylate (Gleevec) is a drug unique for the treatment of certain forms of cancer. It works by targeting, and turning off, specific tyrosine kinase proteins that cause the uncontrolled cell growth and the inhibition of apoptosis in cancer cells. Imatinib was designed on the basis of the...

  • Omacetaxine as an Anticancer Therapeutic: What is Old is New Again. Wetzler, Meir; Segal, David // Current Pharmaceutical Design;1/1/2011, Vol. 17 Issue 1, p59 

    No abstract available.

  • Faktori koji utiču na postizanje i postojanost citogenetskog odgovora kod bolesnika sa hroničnom mijeloidnom leukemijom na terapiji imatinibom. Ćojbašić, Irena; Mačukanović-Golubović, Lana // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Nov2011, Vol. 68 Issue 11, p911 

    Background/Aim. Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has revolutionized the treatment of Bcr-Abl positive chronic myeloid leukemia and become the standard of care for this disease. The aim of this study was evaluation and analysis of cytogenetic response in different...

  • Imatinib.  // Reactions Weekly;1/20/2007, Issue 1135, p18 

    The article discusses a case report on the side effects of imatinib. It references a study by J. C. Pascual et al, published in the December 2006 issue of the "International Journal of Dermatology." It presents two cases of old women who developed lichenoid eruptions during treatment with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics